Transforming old human cells into a youthful and vigorous state is what Regenerative Medicine is all about. Regenerative Therapy is a same-day nonsurgical procedure that involves working on cells and tissues either by replacing, engineering or growing them to establish normalcy. Contrary to surgeries, Regenerative Medicine gets to the root cause of the problem where stem cells communicate with the injured cells to initiate the healing process.

Stimulating the bodys mechanism to repair or heal tissues, regenerative therapy coaxes old human cells to express a panel of proteins involved in embryonic development. As cartilages, tendons, and nerves have limited healing capacity when compared to other parts of the body, regenerative therapies especially target these areas to treat common injuries, orthopedic problems or degenerative joint conditions.

Benefits of Regenerative Medicine

Regenerative medicines nullify the problem of reactions or infections. As it is a non-surgical procedure, it eliminates the pain and complications that occur otherwise. Enhancing healing and recovery, regenerative therapy is quick, long-lasting and mostly preferred by sportspersons. Biologic Products like PRP (platelet-rich plasma) and BMC (bone marrow concentrate) are actively developed for orthopedic procedures, enhancing usage potential and refinement.

PRP(Platelet Rich Plasma)

Focussed on patients platelets and blood cells, PRP releases concentrated proteins following implantation. The released proteins coordinate injured cells and stimulate healing.

BMC (Bone Marrow Concentrate)

Similar to PRP, BMC consists of several stem cells that have the potential to replace themselves as the original cells or can be used to release proteins and communicate with the injured cells to promote healing and repair.

Being an Ivy-trained physician and the founding CEO of Greyledge Technologies, Dr. Karlis medical practice integrates injection-based Regenerative Medicine and Cell Therapy techniques into a traditional non-operative orthopedic and sports medicine approach. Dr. David Karli develops biologic products in the regenerative medicine space. Earlier, degenerative joint problems were treated by blocking or inhibiting the bodys response to injury. Modernizing the traditional approach, Dr. Karli, at Greyledge Technologies prepares biologic products from a patients tissue and puts it back into the same patient. The human blood or bone marrow is processed as implantable materials.

During the biologic processing, he further collaborates with other medical faculty to develop and apply these products onto the injured tissues and stimulate healing. Dr. Karlis passion for regenerative medicine and the evolution of non-surgical procedures for various health problems helped him to develop Platelet Rich Plasma (PRP) and BMC(Bone Marrow Concentrate). The two stem cell injection therapy procedures cure acute and chronic musculoskeletal injuries.

See the original post here:
Familiarizing non-surgical Orthopaedic Treatments with Dr. David Karli - The American Reporter

Bone Marrow Stem Cells Comments Off on Familiarizing non-surgical Orthopaedic Treatments with Dr. David Karli – The American Reporter | May 1st, 2020

What is bone marrow cancer? Types, symptoms and treatment methods you must know  |  Photo Credit: Getty Images

New Delhi: Cancer is becoming a relatively very common disease, among people all around the world. It is a condition where abnormal cells divide uncontrollably in the body and destroy healthy body tissues as well. Cancer usually requires extensive treatment, and can also be life-threatening. Cancer accounted for 9.6 million deaths in 2018, according to WHO. Various popular personalities like Indian actors Irrfan Khan and Rishi Kapoor recently lost their lives to different types of cancer.

Rishi Kapoor was suffering from a bone marrow cancer, and breathed his last on Thursday morning, 30th of April. Here is what you need to know about bone marrow cancer, the cancer veteran actor was suffering from.

The bone marrow is a spongy tissue inside some of our bones. In humans, thesebones include the hips, thighs, etc. The bone marrow is the tissue where stem cells can develop into red blood cells, white blood cells, and platelets, all of which perform specific functions in the body.

Bone marrow cancer is a rare type of cancer. Bone marrow cancer happens when cells in the marrow start growing abnormally. It is a type of blood cancer and not bone cancer. Bone marrow cancer is the type that originates in the marrow and not the type that spreads to the bone or the marrow, after originating in some other part of the body.

Bone marrow cancer can be of various types, depending on the type of cells it affects -

Symptoms of bone marrow cancer vary, according to the type of cells that cancer affects. These include -

Multiple Myeloma Symptoms

Leukaemia symptoms

Lymphoma symptoms

Bone Marrow cancer can be treated by a medical professional. Chances of survival of the patient depend on the stage of cancer, how early the diagnosis is made, and other factors. Treatment methods include -

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read more from the original source:
What is bone marrow cancer? Leukaemia and other types, symptoms and treatment methods you must know - Times Now

Bone Marrow Stem Cells Comments Off on What is bone marrow cancer? Leukaemia and other types, symptoms and treatment methods you must know – Times Now | May 1st, 2020

Now that your makeup layer is gone, you can proceed with washing your face. "A cleanser gets rid of dead skin, pollutants, oils, dirt, and bacteria," says Rabach. Both she and Ciraldo recommend also doing this step when you first wake up in the morning, in order to prep your skin to absorb the active ingredients in your other products.

The best cleanser for you will depend on your skin type. "It's important to pay attention to what's in your cleanser and what's not in it," says Ciraldo. She recommends avoiding sulfates, which can have a harsh, stripping effect on your faceand looking for actives that suit your needs. "For normal or dry skin, I favor a hydrating cleanser with peptides," she says. "If you're oily or acne-prone, use a mild exfoliating cleanser with salicylic acid, which dislodges the dead cells that can clog pores."

Do This Step: Morning and Night

The first product to go on your face? Eye cream. The reason is simplebecause you'll probably forget to do it otherwise. Ciraldo recommends patting eye cream on gently with your ring finger (this way you'll tug less at the delicate skin there) all the way around your eyes, not just underneath them. If you're worried about eye cream causing your concealer or eye makeup to smear, choose a more lightweight option, like a hydrating gel that sinks in quickly and stays put.

For the best results, look for ingredients like peptideswhich help tighten your skin and de-puffas well as antioxidants. Rabach recommends formulas that contain hydrating hyaluronic acid, brightening caffeine, and ceramides (these lock in moisture and help strengthen your skin barrier).

Do This Step: Morning and Night

Both toners and essences are meant to help further prime your skin to absorb active ingredients, but the one you choose will depend on your skin type. Old-school toners were meant to balance skin pH and counteract alkaline soaps, before soap-free cleansers became popular. Now, toner usually refers to liquid formulations geared toward oily skin that's in need of gentle exfoliation and resurfacing. Ciraldo says those with oily or acne-prone skin should look for toners with ingredients like glycolic or salicylic acid.

Essences, on the other hand, tend to be more hydrating. Rabach recommends looking for actives like hyaluronic acid, which will flood your skin with moisture that you can lock in during subsequent steps. To apply, soak a cotton pad in liquid and gently pat it over your face. Alternatively, you can use your hands to do the same thing.

Do This Step: Morning and Night

This is the step where you'll deliver the bulk of active ingredients to your toner/essence-primed face, and it's important to do it early on in your routine. "Serums are formulated with smaller molecular-weight actives so they penetrate into deeper skin layers," says Ciraldo. "If you apply your serum after a thicker formulation, the active ingredients may not penetrate as well."

While you should apply serum twice a day, you shouldn't be using the same formulation. "Serum actives differ for day and night," says Rabach. During the day, she likes to choose serums with antioxidants that protect skin from daytime stressors like free radicals (caused by UV rays), pollutants, and blue light. The most popular ingredient for this is vitamin C, which you will have no problem finding in serum form. (Just make sure to choose one that's properly stabilized for maximum effect.) At night, opt for a serum with peptides and growth factors to repair skin.

For both daytime and nighttime serums, Rabach also has a general list of ingredients she likes to look for across both formulations: Niacinamide to reduce redness, hyaluronic acid to pull moisture into your skin, and alpha and beta hydroxy acids (AHAs and BHAs), which help boost collagen and even out skin pigmentation. Ciraldo further splits up her preferred serum ingredients by skin type. "For acne-prone skin, look for stem cells, retinol, and green tea," she says. "For dehydrated skin, look for lipids, hyaluronic acid, and peptides. And for hyperpigmented skin, look for vitamin C."

Do This Step: At Night Only

Read more from the original source:
Best Skin Care Routine: Order of Products to Use Morning & Night - Glamour

Skin Stem Cells Comments Off on Best Skin Care Routine: Order of Products to Use Morning & Night – Glamour | May 1st, 2020

The GlobalProgenitor Cell Product Market2020 report implement in-depth research of the industry with a focus on the current market trends future prospects. The Global Progenitor Cell Product Market report aims to provide an overview of Progenitor Cell Product Market players with detailed market segmentation by product, application and geographical region. It also provides market share and size, revenue forecast, growth opportunity. The most recent trending report Worldwide Progenitor Cell Product Market Economy by Manufacturers, Regions, kind and application, forecast to 2025 provided bySupply demand Market Researchis an educational study covering the marketplace with detailed analysis.

All the reports consider COVID-19 impact for forecast and analysis.

Feel free to contact us for any inquiry, Get Free PDF Sample Copy of Progenitor Cell Product Market @https://www.supplydemandmarketresearch.com/home/contact/972493?ref=Sample-and-Brochure&toccode=SDMRPH972493

The analysis of Global Progenitor Cell Product Market includes market size, upstream situation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

This report studies the Progenitor Cell Product Market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Progenitor Cell Product Market by product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Global Progenitor Cell Product Market Type (Pancreatic progenitor cells, Cardiac Progenitor Cells, Intermediate progenitor cells, Neural progenitor cells (NPCs), Endothelial progenitor cells (EPC), Others) Application (Medical care, Hospital, Laboratory) Global Trends and Forecasts to 2025

Industry Insights

The Global Progenitor Cell Product Market is expected to grow at a CAGR of XX % during the forecast period 2018-2025.

The Global Progenitor Cell Product Market is segmented on the basis of Type and Application. The Global Progenitor Cell Product Market is segmented based on the basis of typePancreatic progenitor cells, Cardiac Progenitor Cells, Intermediate progenitor cells, Neural progenitor cells (NPCs), Endothelial progenitor cells (EPC), Others. By Application, it is classified as Medical care, Hospital, Laboratory. The regional outlook on the Global Progenitor Cell Product Market covers regions, such as North America, Europe, Asia-Pacific, and Rest of the World. Global Progenitor Cell Product Market for each region is further bifurcated for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Report Scope:

The Global Progenitor Cell Product Market report scope covers the in-depth business analysis considering major market dynamics, forecast parameters, and price trends for the industry growth. The report forecasts market sizing at global, regional and country levels, providing comprehensive outlook of industry trends in each market segments and sub-segments from 2017 to 2024. The market segmentations include

GlobalProgenitor Cell Product Market, By Type

Pancreatic progenitor cells, Cardiac Progenitor Cells, Intermediate progenitor cells, Neural progenitor cells (NPCs), Endothelial progenitor cells (EPC), Others

In the same way, the study has divided by applications

Global Progenitor Cell Product Market, By Application

Medical care, Hospital, Laboratory

GlobalProgenitor Cell Product Market, By Region

The report scope also includes competitive landscape covering the competitive analysis, strategy analysis and company profiles of the major market players. The companies profiled in the report includeNeuroNova AB, StemCells, ReNeuron Limited, Asterias Biotherapeutics, Thermo Fisher Scientific, STEMCELL Technologies, Axol Bio, R&D Systems, Lonza, ATCC, Irvine Scientific, CDI

Report Highlights

How this report will add value to your organisation

This report provides the in-depth analysis of the complete value chain from the raw material suppliers to the end users. We have critically analysed following parameters and their impact in the industry:

1. Improvement in top line and bottom line growth

Analysis trend & forecasts by end use markets will help you to understand how the growth in consumption is expected in next 5 years and what will be the key factors that will support the growth. This will help to make a clear plan for the top line growth. Price analytics will also play a crucial role in making a plan for top line growth.

Raw material and other input factors analysis will help to plan effectively for the bottom line.

2. Competitive intelligence

In a competitive marketplace, up-to-date information can make the difference between keeping pace, getting ahead, or being left behind. A smart intelligence operation can serve as an early-warning system for disruptive changes in the competitive landscape, whether that change is a rivals new product or pricing strategy or the entrance of an unexpected player into your market.

We also provide you with information that allows you to anticipate what your competitors are planning next. For example, you might gain information on a new product they are getting ready to launch or new services they will add to the business. Hiring us to handle this information collection saves you time and energy, allowing you to focus on your own business while still gaining the necessary knowledge to keep track of competitors.

3. Identification of prospective customers and their satisfaction level with the current supplier:

We have provided the long list of customers and analysed them critically, based on various parameters such as consumption, market type, sustainable business etc. this will help your organisation to develop relations with the consumers. Also, we have identified the factors in which the others customer will switch to you.

Report Customizations

The customization research services cover the additional custom report features such as additional regional and country level analysis as per the client requirements.

Get More Information About Full Report Progenitor Cell Product Market @https://www.supplydemandmarketresearch.com/home/contact/972493?ref=Discount&toccode=SDMRPH972493

This comprehensive report can be a guideline for the industry stakeholders that helps in analyzing the Progenitor Cell Product Market and forecast of till 2024. This report aids to detection of the projected market size, market status, future predictions, growth prospect, main challenges of Progenitor Cell Product Market by analyzing the segmentations.

In the following section, the report provides the Progenitor Cell Product Market company outline, statements of the product, and performance values. With the support of the arithmetical study, the report demonstrates the complete international Progenitor Cell Product Market market inclusive of amplitude, production, manufacturing value, loss/gain, Progenitor Cell Product Market supply/demand and import/export. The Progenitor Cell Product Market report is divided into key companies, by regions, and by various sectors such as application, type for the competitive landscape analyze.

Analysis of various Progenitor Cell Product Market categories of product and end-user applications, product types of Progenitor Cell Product Market is estimated on the basis of previous market and present market scenario. It involved Global Progenitor Cell Product Market values with respect to growth rate, market size, and share and consumption. Further, it gives details, prerequisite, and features of Progenitor Cell Product Market that boost the growth of the industry.

About Us:

We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us:

Nimesh H

302-20 Misssisauga, Valley, Missisauga,

L5A 3S1, Toronto, Canada

Phone Number: +1-276-477-5910

Email- [emailprotected]

See the original post here:
Progenitor Cell Product Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2025 ...

Cardiac Stem Cells Comments Off on Progenitor Cell Product Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2025 … | May 1st, 2020

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Report Highlights:

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Link:
Induced Pluripotent Stem Cells Market to Witness CAGR 8.7% Growth in Revenue During the Period 2026 - Cole of Duty

Skin Stem Cells Comments Off on Induced Pluripotent Stem Cells Market to Witness CAGR 8.7% Growth in Revenue During the Period 2026 – Cole of Duty | April 30th, 2020

Transparency Market Research (TMR)has published a new report on theamniotic membrane marketfor the forecast period of2019-2027. According to the report, the global amniotic membrane market was valued at ~US$ 980 Mnin2018and is projected to expand at a CAGR of ~10%from2019to2027.

GlobalAmniotic Membrane Market:Overview

Request for Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42059

Increase in Research on Stem Cell Biology & Regenerative Medicineto Drive Market

Cryopreserved Amniotic Membrane Products to Dominate Market

Request for Analysis of the COVID19 Impact on Amniotic Membrane Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42059

Ophthalmology to be Promising Application

Hospitals Account for Major Share of Global Market

North America to Dominate Global Amniotic Membrane Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=42059

Global Amniotic Membrane Market: Competitive Landscape

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email:sales@transparencymarketresearch.comWebsite:https://www.transparencymarketresearch.com

Originally posted here:
Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain - BioSpace

Skin Stem Cells Comments Off on Amniotic Membrane Market: Locally Available Amniotic Allografts Increasingly Meeting Needs of Patients with Joint Pain – BioSpace | April 30th, 2020

Home Topics Lung Infection

Mesoblast announced data from a phase 2/3 trial evaluating remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS).

Remestemcel-L consists of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is believed to work by down-regulating the production of proinflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

The randomized, placebo-controlled trial is being conducted at Mount Sinai hospital in New York City. Patients were treated with a variety of experimental agents prior to receiving remestemcel-L. Findings from the study showed 83% survival in ventilator-dependent COVID-19 patients with moderate/severe ARDS (n=10/12) following 2 intravenous infusions of remestemcel-L within the first 5 days; 75% of patients (n=9/12) were able to successfully come off ventilator support at a median of 10 days. There have been 7 patients discharged from the hospital as of now.

Mesoblast Chief Executive Dr. Silviu Itescu stated: The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

Additionally, the Food and Drug Administration recently accepted for Priority Review the Biologics License Application of remestemcel-L for the treatment of steroid-refractory acute graft vs host disease. The Company expects to launch remestemcel-L in 2020 if approved.

For more information mesoblast.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Lung InfectionClose

Continue reading here:
Remestemcel-L Looks Promising for COVID-19 With Moderate to Severe ARDS - Pulmonology Advisor

Bone Marrow Stem Cells Comments Off on Remestemcel-L Looks Promising for COVID-19 With Moderate to Severe ARDS – Pulmonology Advisor | April 30th, 2020

BACKGROUND:

Osteoporosisis a metabolic bone disease characterized by low bone density resulting in increased fracture susceptibility. This research was constructed to uncover the potential therapeutic application of osteoblasts transplantation, generated upon culturing male rat bone marrow-derived mesenchymal stem cells (BM-MSCs) in osteogenic medium (OM), OM containing gold (Au-NPs) or gold/hydroxyapatite (Au/HA-NPs) nanoparticles, in ovariectomized rats to counteractosteoporosis.

Forty rats were randomized into: (1) negative control, (2) osteoporotic rats, whereas groups (3), (4) and (5) constituted osteoporotic rats treated with osteoblasts yielded from culturing BM-MSCs in OM, OM plus Au-NPs or Au/HA-NPs, respectively. After 3months, osterix (OSX), bone alkaline phosphatase (BALP), sclerostin (SOST) and bone sialoprotein (BSP) serum levels were assessed. In addition, gene expression levels of cathepsin K, receptor activator of nuclear factor-b ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio were evaluated using real-time PCR. Moreover, histological investigation of femur bone tissues in different groups was performed. The homing of implanted osteoblasts to the osteoporotic femur bone of rats was documented by Sex determining region Y gene detection in bone tissue.

Our results indicated that osteoblasts infusion significantly blunted serum BALP, BSP and SOST levels, while significantly elevated OSX level. Also, they brought about significant down-regulation in gene expression levels of cathepsin K, RANKL and RANKL/OPG ratio versus untreated osteoporotic rats. Additionally, osteoblasts nidation could restore bone histoarchitecture.

These findings offer scientific evidence that transplanting osteoblasts in osteoporotic rats regains the homeostasis of the bone remodeling cycle, thus providing a promising treatment strategy for primaryosteoporosis.

The rest is here:
Osteoblast-Based Therapy-A New Approach for Bone Repair in Osteoporosis: Pre-Clinical Setting - DocWire News

Bone Marrow Stem Cells Comments Off on Osteoblast-Based Therapy-A New Approach for Bone Repair in Osteoporosis: Pre-Clinical Setting – DocWire News | April 30th, 2020

Thefirst-in-human, universal chimeric receptor antigen (CAR) T-cell (CAR-T)therapy GC027 was tolerable and resulted in antileukemic responses amongpatients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL),according to results from a phase 1 trial presented at the American Associationfor Cancer Research (AACR) Virtual Annual Meeting I 2020.1

The universal CAR T cells target CD7, which, according to Xinxin Wang, PhD, of Gracell Biotechnologies Co, Ltd, in China, and lead author and presenter of the study, is a good target for T-ALL because it is expressed by more than 95% of T-ALL patients.

GC027 isallogeneic, which may prevent the development of graft-versus-host disease. Theproduct is introduced using lentivirus for rapid elimination of T-ALL cells. Preclinicalstudies showed efficacy in a T-ALL xenograft model, and this prospective studyevaluated the safety and efficacy in humans.

Thesingle-arm, open-label study treated 5 adult patients with relapsed/refractoryCD7-positive T-ALL with a single infusion of 1 of 3 different dose levels ofG027: 0.6 x 107/kg, 3 x 107/kg, and 1.5 x 107/kg.Lymphodepletion therapy was administered prior to the G027 infusion. Theprimary endpoint was safety and the secondary endpoints included objectiveresponse rate (ORR) within 3 months after G027 infusion.

Patients with extramedullary or central nervous system disease were excluded. At baseline, the median age was 24 (range, 19-38). Patients were heavily pretreated, with 5 median number of prior therapies (range, 1-9). Two patients had high-risk disease and the median bone marrow tumor burden was a median of 38.2% of blasts. None of the patients had undergone a prior allogeneic hematopoietic stem cell transplant.

Allpatients developed cytokine release syndrome (CRS), 4 of which were grade 3 and1 was grade 4. All cases were manageable and resolved with treatment andsupportive care. None of the patients developed neurotoxicity.

The completeremission (CR)/CR with incomplete hematologic recovery was 100%. By day 28, 4patients achieved a CR with negative for minimal residual disease (MRD) and 3of these patients remained MRD negative up to day 161. One patient achieved CRbut was MRD positive, and relapsed by day 29.

Peak CART-cell expansion in peripheral blood occurred between week 1 and 2.

As the first-in-human, universal CAR T-cell therapy for adult relapsed/refractory T-ALL, Dr Wang said, GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. She added that trial enrollment is ongoing.

Reference

Wang X, Li S, Gao L, et al. Clinical safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27-28, 2020. Abstract CT052.

This article originally appeared on Cancer Therapy Advisor

More here:
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL - Hematology Advisor

Bone Marrow Stem Cells Comments Off on First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL – Hematology Advisor | April 30th, 2020

This Placental Stem Cells (PSCS) industry report provides comprehensive analysis as follows Market segments and sub-segments, Market size, Market trends and flow, Major Manufacturers Production and Sales Market Comparison Analysis, Drivers and Opportunities, Competitive scene, Product Specification and Major Types Analysis, Supply and demand, Regional Production Market Analysis, Regional Market Performance and Market Share. The Placental Stem Cells (PSCS) market research report covers effectiveness and summary of the marketing research. These results can be employed to make improvements in the business. The report helps to save a large amount of time and money that may get spend on marketing.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market

Placentalstem cells(PSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

The major players covered in theplacental stem cells (PSCS) marketreport areCBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market Analysis and Insights of Global Placental Stem Cells (PSCS) Market

Adoption of advances and novel technologies that will lead to the storage and preservation of stem cells, technological advancement in the field of biotechnology, introduction of hematopoietic stem cell transplantation system and growing number of diseases which will helps in accelerating the growth of the placental stem cells (PSCS) market in the forecast period of 2020-2027. Surging number of applications from emerging economies along with rising awareness among the people will further boost many opportunities that will led to the growth of the placental stem cells (PSCS) market in the above mentioned forecast period.

Increasing operation costs along with stringent regulatory framework will likely to hamper the growth of the placental stem cells (PSCS) market in the above mentioned forecast period. Social and ethical issues will be the biggest challenge in the growth of the market.

Thisplacental stem cells(PSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on placental stem cells (PSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Placental Stem Cells (PSCS) Market Country Level Analysis

Placental stemcells(PSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The countries covered in the placental stem cells (PSCS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bone marrow-derived stem cells (BMSCS) market due to the increasing stem cell procedure along with preferences of private stem cell banking over public and surging network of stem cell banking services.

The country section of the placental stem cells (PSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Placental stem cells (PSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for placental stem cells (PSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the placental stem cells (PSCS) market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Placental Stem Cells (PSCS) Market Share Analysis

Placental stem cells (PSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to placental stem cells (PSCS) market.

To Get This Report at an Attractive Cost, Click Herehttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.com

See original here:
Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell...

Bone Marrow Stem Cells Comments Off on Placental Stem Cells (PSCS) Market is Prospering With Healthy CAGR in 2020. Leading Players are Cryo-Cell International, Inc., ESPERITE NV, LifeCell… | April 30th, 2020

VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced updates on 49 COVID-19 patients who have received leronlimab under the U.S. Food and Drug Administration's (FDA) emergency Investigational New Drug (eIND) program:

Eleven (11) Patients in NY hospital: All treated patients were in Intensive Care Units (ICU) because of acute respiratory failure, eight of whom were intubated (placed on mechanical ventilation). One patient was not intubated because of poor baseline pulmonary status (history of lung cancer and had undergone bilateral upper lobectomy). Seven patients were organ-transplant recipients (six patients were renal-transplant recipients and one patient had a history of heart transplant) and were on immunosuppressive regimen. Ten patients were on dialysis and nine were on vasopressors during hospitalization. Despite their pre-existing and severe conditions, we believe we were able to save the lives of four patients. All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients. This data has been submitted to a prestigious journal and we expect the publication on Friday, May 1.

Twenty-three (23) patients in Southern California hospital: Six patients were in critical condition (intubated) and 17 patients were severely-ill, needing oxygen support. No death was reported. Out of 6 critical patients, all were intubated patients, 3 were extubated (taken off ventilator), 2 patients remain relatively stable and still breathing with the assistance of a ventilator and one patient has shown deterioration in respiratory parameters. Of 17 severe condition (but not critical) patients, 11 patients demonstrated improvement in respiratory parameters (8 of them were discharged from hospital, including one patient in the news, Samantha Mottet), 2 patients remain relatively stable, 2 have shown deterioration in respiratory parameters and information is pending for 2 recently treated patients.

Three (3) patients in Georgia hospital: All three ICU patients were intubated and two of them had renal failure at the start of leronlimab treatment. Of these 3 patients, 2 were extubated (taken off ventilator) and 1 patient remains on a ventilator but improving.

One (1) patient in another NY hospital: Patient was taken off oxygen and discharged from hospital after leronlimab treatment.

One (1) patient in Northern California hospital: Patient is now weaning from ventilator and transferred to rehabilitation hospital.

Updates are pending for 10 other patients. Five additional patients have been approved to receive leronlimab under eINDs, which increases the total eINDs approved by the FDA to 54 patients.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, "We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days."

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, "We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing. The enrollment for our Phase 2 double-blind and Phase 2b/3 trials is moving along rapidly and we believe the results from both studies will be very powerful due to the mechanism of action (MOA) of affecting the viral load and restoring the immune system. With our first major paper very close to publication, we expect to have a second paper published shortly thereafter, as our MOA is as unique as our results."

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Company's cash position, (ii)the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv)the Company's ability to enter into partnership or licensing arrangements with third parties, (v)the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Company's ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Company's clinical trials, (viii)the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

See more here:
CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -...

Bone Marrow Stem Cells Comments Off on CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -… | April 30th, 2020

India with its huge population can become an ideal place for medical research in stem cell, but due to lack of awareness and investment, its progress is slowing down. Vipul Jain, CEO, Advancells talks about the companys vision for stem cell research and progress in India, to Usha Sharma

Give us a brief about your companys inception?

I have been a part of healthcare marketing for over 12 years now and somewhere in 2009-10, a few patients started talking about stem cell therapies if I could help them find a centre, where they could opt for these therapies. Unfortunately, none such centre operated in India and there were very few across the world. Once I studied the subject in-depth it occurred to me that this would be the future of medicine and it was the right time to enter this field. The hope of changing medicine as we know it today inspired me to get into this practice and I established Advancells in 2013.

In the past seven years of our operations, we have grown strength to strength and are today one of the largest providers of stem cell therapies in India.

When we started Advancells, we aimed at becoming a pioneer in the research and development of regenerative medicine. We wanted to have India at the forefront of protocols and technologies in the industry and so we decided to venture into a wide array of services. In order to become a centre of medical advancement, we had to ensure we offered services to all sorts of patients, irrespective of their condition. We believe in treating our patients in a progressive manner.

Tell us about the challenges you faced while setting up your business?

Lack of investment is the biggest challenge. Most new investments in healthcare sector still come from Trusts and charities who enter the segment for charity and with a no-profit no-loss mindset. This restrains their capacity to invest in research and new technologies and hence it is not easy to get cutting edge technologies in the country. India with its huge population base can be a perfect place for strong medical research but the lack of awareness and investment are the major reasons for India to lag behind in research. It is not easy for healthcare researchers to attract private money as private investors are worried about the long gestation period for their investment.

The other major challenge is the acceptance of doctors of a new branch of medicine. It is very difficult to convince doctors of a new way to treat patients and understandably they want long term follow-up data. This data will take time to come and hence growth can not be as fast as you expect it to be. Government regulations are another challenge as agencies are always a little slow to react to innovation.

The expense of research and clinical preliminaries is high in the case of regenerative medicine, in this way confining the research objectives. Aside from cost/enormous speculations, other challenges are administrative difficulties with changing rules across nations, on account of contrasts in the suppositions and social perspectives. Setting up a solitary/regular arrangement or rule worldwide to administer stem cell research could be helpful. Human embryos for research, somatic cell, nuclear move, IPSCs have raised concerns due to their long hatching periods.

So how does your model work?

Advancells works in four different verticals. Firstly, we produce basic human stem cells that are used by partner hospitals and doctors in providing regenerative therapies to the patients. Advancells also writes protocols for therapies and provide training to doctors on various facets of regenerative medicine. In the second vertical, we produce organ, species and disease-specific primary cells, which are used by research institutes, academic institutes and pharma companies around the world to further their research in the field of biology and drugs.

In the third vertical, we produce our patented range of bioscaffolds which once seeded with our cells, are used in the regeneration of bones, organs and healing of wounds. Fourthly, we print 3D human organs and finally seed our scaffolds with our primary cells and paste them on the 3D printed organ models and try to create working modal of a human organ that can be used by pharma companies for drug discovery models. Our moonshot is to be able to produce a transplantable human artificial organ that can one day put an end to mortality rate due to non-availability of transplantable human organs.

We are essentially a B2B business where doctors and hospitals, research institutes, pharma companies etc., are our clients, but we regularly get approached by a number of patients both from India and abroad who want our protocols for treatment. We do provide B2C services to such patients also.

We are currently operating out of our centralised lab in Noida, Delhi/NCR and are able to ship cells to various hospitals not just across India but also in various countries around the world.

Does India have well-defined stem cell treatment regulations?

Surprisingly very well. India has been always been a follower especially when it comes to medical research. There has hardly been any major medical innovation that has come out of India but things seem to be changing this time. It looks like there will be a good case study where India might just take the lead in stem cell technology and be a world leader in it. We have all the required resources and brainpower to make it happen, all we need is a supportive legislature, progressive regulators, understanding investors and gritty innovators and you will see things rolling.

The Government of India has started promoting Stem Cell Research with the help of its agencies. The focus is on identifying diseases and conditions that can be cured. Programmes to support embryonic and adult stem cell research are in place. Some of the developments include setting up human embryonic stem cell lines, using limbal stem cells to repair corneal surface disorder; classification of haematopoietic, mesenchymal and liver stem cells; as well as segregation of stem cells into neural, cardiac and cell lineages, etc.

For the rest of the world, there are many researchers who are creating pathbreaking records. Scientists from the University of California, for instance, have created an approach via stem cells to deal with cancerous tissue while anticipating some dangerous reactions of chemotherapy by treating the disease in a progressive manner.

So whats the scope for stem cell research/ therapy?

Stem cells present a unique opportunity to treat the disease that currently is termed as untreatable. They also help us in treating the diseases from the core and not just managing the symptoms. These properties give regenerative medicine a unique status.

You conduct 15-20 treatment in a month despite the unclear regulations in India? Do you see this as a challenge and deal with it?

We deal only with hospitals and doctors who have taken permission from the government and hence the reach is very low.

How do you differentiate your therapies from other existing players? What all guideline you follow and what is the success ratio?

There is no real credible competition for us. The big players in the market are primarily into cord blood banking and for the therapy is a side product on which they dont concentrate. There are few doctors who practice regenerative medicine on their own but could never match up with the product catalogue or research backing that we have.

There is an exhaustive consent form and clear inclusion and exclusion criterion and the patients are council-led at multiple points before the procedure.

Which are the therapeutic areas Advancells provides stem cell solutions and how safe are they? What is your future plan?

Advancells provide stem cell solutions for orthopaedics, neurology, diabetes etc. It is completely safe. We are targeting to venture into Cosmetics, Ophthalmology.

[emailprotected]

[emailprotected]

Originally posted here:
Lack of investment is the biggest challenge in stem cell research - Express Healthcare

Cardiac Stem Cells Comments Off on Lack of investment is the biggest challenge in stem cell research – Express Healthcare | April 30th, 2020

When the ISS reaches its retirement date, the Axiom complex will detach and operate as a free-flying commercial space station.

This is the second contract SpaceX grabbed as it reached an agreement with Space Adventures on February 18 to launch private citizens on Crew Dragon spacecraft into an Earth orbit higher than ISS between late-2021 to mid-2022.

SpaceX will attempt to land the rocket booster back at Cape Canaveral, meaning residents in the area could hear a sonic boom. "This will be just the first of many missions to ISS to be completely crewed and managed by Axiom Space - a first for a commercial entity". In 2014, SpaceX and Boeing snagged a coveted launch contract collectively worth $6.8 billion to each build a spacecraft capable of transporting astronauts to the space station and back.

B1059 returned to Port Canaveral on December 7th, 2019 and will launch CRS-20 - its second Dragon mission - nearly exactly three months later. The flight's crew will live onboard the existing station for at least eight days.

When Dragon does return home, it will mark the end of SpaceX's original Commercial Resupply Services (CRS) contract with NASA. While this is not an issue for astronauts on board, as food from Earth is supplied regularly, for long-duration spaceflight-like those to the moon and Mars, which NASA is now planning-the issue of nutrition could become a problem.

Among the payloads on the Dragon is Bartolomeo, an external experiment platform developed by Airbus that will be installed on the station's Columbus module. The Earth views are supposed to be spectacular. Potential applications include Earth observation, robotics, material science and astrophysics. Studying these "tissue chips" may provide a better understanding on how they may cause disease on Earth.

Generation of Cardiomyocytes From Human Induced Pluripotent Stem Cell-derived Cardiac Progenitors Expanded in Microgravity (MVP Cell-03) examines whether microgravity increases the production of heart cells from human-induced pluripotent stem cells (hiPSCs).

"Since 2012, SpaceX has been delivering cargo to the International Space Station in partnership with NASA and later this year, we will fly NASA astronauts for the first time", said SpaceX President and Chief Operating Officer Gwynne Shotwell.

These are just a few of the hundreds of investigations providing opportunities for US government agencies, private industry, and academic and research institutions to conduct microgravity research that leads to new technologies, medical treatments and products that improve life on Earth.

Axiom Space is inviting individuals seeking out a trip of a lifetime.

A lot of the packaged food loses its nutritional value over time in Space, so it has been one of NASA's prime focuses to find products that can be grown on the ISS so as to provide astronauts with proper nutrition, as well as keeping their morale high.

Excerpt from:
SpaceX, Axiom to send three tourists to ISS in 2021 - ClickLancashire

Cardiac Stem Cells Comments Off on SpaceX, Axiom to send three tourists to ISS in 2021 – ClickLancashire | April 30th, 2020

- Advertisement -

Doctors treating severe COVID-19 instances in New York attempted stem cell treatment on 12 patients, 10 of whom came off ventilators after receiving treatment.

It is uncertain whether the publication coronavirus disease could be treated with stem cells, but scientists in Mesoblast are going to conduct a clinical trial on 300 serious patients to find more replies.

Anecdotal evidence suggests that stem cells can be helpful, however, the science behind it has to be clarified. The book coronavirus might not have a remedy right now, but it is still worth noting the huge research effort which goes into discovering treatments that could restrict COVID-19 complications and prevent death.

Doctors have observed the positive effects of a garden range of drugs that are supposed to treat other disorders, and some of these medicines are contained in enormous trials across the world. Scientists are also working on over 70 vaccine applicants for COVID-19, using some of them showing promising results. In addition to that, theres plasma from predators that is rich in antibodies which may help individuals with weaker immune systems.

And doctors think they have found another promising remedy for COVID-19: Stem cells. You frequently hear about stem cells and these reports are often miraculous. Stem cells are human cells which have thesuperpower to change into just about any cell of their human body and they can be used to treat some health problems. Stem cells can regenerate lung tissue, fight inflammation, and help acute COVID-19 patients breathe on their own back.

Doctors at Mount Sinai treated 12 patients with stem cell treatment, and 10 of these came off their ventilators soon after, CBSNews reports. The doctors themselves have no idea what helped the patients improve, and cant definitively say that its the stem cells that stored their patients.

What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better, Dr. Karen Osman advised CBS. The doctor made it clear they cant claim the stem cell treatments are what saved the sufferers. We dont know, she said. And wed never dare to assert that it had been associated with the cells.

The doctor explained that just a randomized controlled trial would have the ability to inform them whether the stem cells can assist with the recovery of COVID-19 patients. Thankfully, one particular study is going to get underway. Mesoblast will trial stem cell treatments on 300 patients suffering from severe lung inflammation. Osman and her staff think that stem cells extracted from bone marrow could suppress the inflammation in COVID-19 patients, and that is why they tried the treatment. Naranjo has recovered following stem cell treatment, and hes at home focusing on regaining his strength.

The miracle treatment is going to be a vaccine. While we await any Type of effective COVID-19 treatment, heres a simple explainer for stem cells:

- Advertisement -

Follow this link:
New York Is Going To Conduct Stem Cell Treatment For COVID-19 Patients - World Top Trend

Bone Marrow Stem Cells Comments Off on New York Is Going To Conduct Stem Cell Treatment For COVID-19 Patients – World Top Trend | April 30th, 2020

Doctors are hoping stem cell therapy could be a weapon in the fight against coronavirus. On Friday, regenerative medicine company Mesoblast announced a 300-person trial to determine whether stem cell treatments will work in COVID-19 patients suffering from severe lung inflammation.

One hospital in New York tried it as an experiment with 12 patients, 10 of whom were able to come off of ventilators.

"What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better," Dr. Karen Osman, who led the team at Mount Sinai, told CBS News' Adriana Diaz.

The doctor said she was encouraged by the results, though she was hesitant to link the stem cell procedure to her patients' recovery.

"We don't know" if the 10 people removed from ventilators would not have gotten had they not gotten the stem cells, she said. "And we would never dare to claim that it was related to the cells."

She explained that only a "randomized controlled trial" would be the only way "to make a true comparison."

Luis Naranjo, a 60-year-old COVID-19 survivor, was one of Mount Sinai's stem cell trial success stories. He told Diaz in Spanish that he was feeling "much better."

Naranjo's daughter, Paola, brought him to the emergency room, fearful she would not see her father again. Like so many families struck by the coronavirus, she was not allowed inside with him.

"I forgot to tell him that I love him," she said. "All I said was go inside, I hope you feel better."

During his hospital stay, Naranjo was unconscious and on a ventilator for 14 days.

Doctors proposed giving him stem cells from bone marrow in hopes it would suppress the severe lung inflammation caused by the virus.

Now, Naranjo credits the doctors who treated him for his survival. Though income from his family's jewelry business has been cut off and they found themselves falling behind on rent, Naranjo said he is focused primarily on his recovery and regaining the 25 pounds he lost at the hospital.

Although stem cell treatment, usually reserved for other diseases like rheumatoid arthritis, might end up being another step toward helping coronavirus patients recover, Dr. Osman was quick to say it would not be a "miracle treatment."

"The miracle treatment will be a vaccine," she said.

Read more:
Doctors experiment with unproven stem cell therapy on COVID-19 patients - CBS News

Bone Marrow Stem Cells Comments Off on Doctors experiment with unproven stem cell therapy on COVID-19 patients – CBS News | April 30th, 2020

BOCA RATON, Fla., April 29, 2020 /PRNewswire/ -- While most of the country has been on lockdown due to the coronavirus crisis, Gift of Life Marrow Registry donor Drake Jackson, traveled 1,000 miles to save the life of a stranger by donating his stem cells to a cancer patient in need of an urgent transplant. The 23-year-old was inspired by his hero and MLB professional baseball player Matt Szczur, who, in 2009 donated bone marrow to a young leukemia patient he had never met.

Jackson was an undergraduate at Illinois State University when he heard of Szczur's heroic act. "I'm a Chicago Cubs fan and when I found out that Matt [who played for the team at the time] had made this incredible donation to save a life, I felt that joining the registry was an easy thing to do to possibly help someone," said Jackson.

So, in November 2016, Jackson searched the internet and found Gift of Life Marrow Registry. He ordered a swab kit online and three years later he was called as a match for a patient battling leukemia.

Jackson was at work when Gift of Life's call came. Undaunted by the growing pandemic, he traveled to Florida in March from Illinois to the Dr. Miriam and Sheldon G. Adelson Gift of Life-Be The Match Collection Center to donate his lifesaving stem cells. "I encourage anyone to join the registry. It's super easy and everyone at Gift of Life is amazing, said Jackson."

After his procedure, Jackson connected with Szczur on social media and the two bonded over their experience as donors. So, when Jackson decided to shift his weddingoriginally planned for May in Key Westonline on April 22, Szczur's participation via video came as a special gift.

"I was honored to have been able to give a child a chance to live out her life when I donated bone marrow all those years ago," said Szczur. "To learn about the ripple effect of not only helping to save a life, but also inspiring Drake to do the same, is truly amazing. In these times of great difficulty, his story brings hope and a reminder that it takes just one person to make a difference."

To join the Gift of Life registry from home, potential donors can request a registration kit at giftoflife.org/register.

About Gift of Life Marrow RegistryGift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life Marrow Registry, visit http://www.giftoflife.org.

Media contact: Edwige Buteau, Gift of Life Marrow RegistryOffice: +1 (516) 982-2921; Cell: +1 (917) 655-3843; [emailprotected]

SOURCE Gift of Life Marrow Registry

http://www.giftoflife.org

Go here to read the rest:
MLB Player Inspired Baseball Fan To Save Life Of Leukemia Patient During Pandemic - PRNewswire

Bone Marrow Stem Cells Comments Off on MLB Player Inspired Baseball Fan To Save Life Of Leukemia Patient During Pandemic – PRNewswire | April 30th, 2020

In an unfortunate development, actor Rishi Kapoor lost his long battle with Leukemia. As we all know, the actor had travelled to the US for his treatment earlier and came back looking younger and healed. But he has had his share of health issues ever since. The family had been referring to the treatment as marrow and today the family confirmed that the actor was struggling with leukemia. Let us first understand what leukemia is - Leukemia is cancer of the body's blood-forming tissues, which includes the bone marrow as well as the lymphatic system. There are several types of leukemia, and some even affect the children, however, mostly leukemia occurs in adults. According to Cancer.org, most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. . To understand the course of treatment that the actor may have undergone, we spoke exclusively to subject matter expert Dr Rahul Bhargava, Director, Haematology, Haemato - Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. The doctor says the way it appears, the star must have suffered from Acute myeloid leukemia (AML) which is a cancer that starts in the bone marrow, which is the soft inner part of certain bones, where the body makes new blood cells. This often quickly moves into the blood, as well. Talking about the treatment for this particular illness, Dr Bhargava said, There is a possibility that he underwent a MUD (Match unrelated donor) transplant with reduced intensity conditioning (RIC), which basically means that he was given a lower intensity treatment, considering his age. How does MUD work?In MUD, stem cells from outside are injected in the body, and mature stem cells are targeted and removed. A person has to be in the hospital for close to 21-25 days for this procedure and then we wait and see how the body responds to the treatment. The doctor adds that clearly the treatment couldnt control his disease and he succumbed to it.

See the article here:
Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment - Times of India

Bone Marrow Stem Cells Comments Off on Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment – Times of India | April 30th, 2020

A novel,bispecific CD19/CD22 chimeric antigen receptor T-cell (CAR-T) therapy wastolerable and resulted in responses among patients with acute lymphoblasticleukemia (ALL), according to results from a phase 1 trial presented at the AmericanAssociation for Cancer Research (AACR) Virtual Annual Meeting I 2020.

Thenovel CAR-T therapy was developed with the hypothesis that dual antigen-targetingstrategies may prevent antigen negative escape, Haneen Shalabi, DO, of theNational Cancer Institute and lead author and presenter of the study, said.

Thephase 1, dose-escalation study treated 13 young patients with ALL with theCD19/CD22 CAR-T therapy at 3 different dose levels, including 3 x 105,1 x 106, and 3 x 106. The bispecific construct containedFMC63 (CD19 scFv) linked with m971 (CD22 scFv) and a 4-1 BB costimulatorydomain.

Patientsunderwent lymphodepletion with fludarabine plus cyclophosphamide prior to theirCAR-T infusion. The primary endpoints were safety and toxicity, and thesecondary endpoints were efficacy, chimeric antigen receptor (CAR) expansion,and CAR persistence.

Atbaseline, the median age was 19.6 (range, 5.4-28.5). Patients had receivedprevious treatments, including hematopoietic stem cell transplant (54%),CD19-targeted therapy (69%), prior CD19 CAR T cell therapy (38.4%),blinatumomab (61.5%), CD22-targeted therapy (38.4%), inotuzumab (30.7%), andCD22 CAR-T therapy (15.4%). Extramedullary disease was present in 46.2% ofpatients.

CAR Tcells were well tolerated and toxicities were reversible in all patients, DrShalabi said.

Cytokinerelease syndrome (CRS) developed in 46% of patients, 15.4% of which was grade 3or higher. Both patients who developed grade 3 or higher CRS had received the 1x 106 dose level of the CD19/CD22 CAR-T product and both requiredtreatment with tocilizumab. One patient developed neurotoxicity, and hadreceived the 3 x 106 dose level.

Of the12 patients evaluable for efficacy, a complete response (CR) was achieved by42% (5) of patients, including all patients who received the 1 x 106 or 3 x 106 dose levelsof the CD19/CD22 CAR-T therapy. There were 2 nonresponders.

Two patientswho received 1 x 106 CAR-T and all patients who received the 3 x 106dose level were negative for minimal residual disease (MRD), with the remainingCRs demonstrating bone marrow clearance. Four of the 5 patients who were MRDnegative were also naive to CAR-T therapy.

Of the 5patients who achieved a CR, 2 relapsed with CD19-positive/CD22-positive diseaseand 3 remained in remission at a median 7 months after CAR T cell infusion.

Severalpatients, however, who were MRD negative in the bone marrow did not achieve CRin their extramedullary disease. Dr Shalabi said that these discrepant resultsbetween marrow and extramedullary disease suggests potentially limited CAR-Ttrafficking to sites of extramedullary disease. She suggested that treatmentat higher dose levels may be needed to overcome this limitation.

CAR T-cellexpansion occurred in all patents who responded, with a median peak inperipheral blood of 7%. At day 28, there were 1.3% CAR T cells in the bonemarrow. The persistence of the CAR T cells in peripheral blood was a median of45.6 days, as measured by flow cytometry.

Dr Shalabi concluded that this early experience with bispecific CD19/CD22 CAR T cells demonstrates clinical activity with reversible CRS and limited neurotoxicity. She noted that future studies will explore a 1 x 107 dose level, intensification of lymphodepletion prior to CAR-T infusion, and consideration of the potential role of immune checkpoint inhibitors to augment CAR-T in extramedullary disease.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

References

Shalabi H, Yates B, Shahani S, et al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020; April 27-28, 2020. Abstract CT051.

See the article here:
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL - Cancer Therapy Advisor

Bone Marrow Stem Cells Comments Off on Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL – Cancer Therapy Advisor | April 30th, 2020

Thefirst-in-human, universal chimeric receptor antigen (CAR) T-cell (CAR-T)therapy GC027 was tolerable and resulted in antileukemic responses amongpatients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL),according to results from a phase 1 trial presented at the American Associationfor Cancer Research (AACR) Virtual Annual Meeting I 2020.1

Theuniversal CAR T cells target CD7, which, according to Xinxin Wang, PhD, ofGracell Biotechnologies Co, Ltd, in China, and lead author and presenter of thestudy, is a good target for T-ALL because it is expressed by more than 95% ofT-ALL patients.

GC027 isallogeneic, which may prevent the development of graft-versus-host disease. Theproduct is introduced using lentivirus for rapid elimination of T-ALL cells. Preclinicalstudies showed efficacy in a T-ALL xenograft model, and this prospective studyevaluated the safety and efficacy in humans.

Thesingle-arm, open-label study treated 5 adult patients with relapsed/refractoryCD7-positive T-ALL with a single infusion of 1 of 3 different dose levels ofG027: 0.6 x 107/kg, 3 x 107/kg, and 1.5 x 107/kg.Lymphodepletion therapy was administered prior to the G027 infusion. Theprimary endpoint was safety and the secondary endpoints included objectiveresponse rate (ORR) within 3 months after G027 infusion.

Patientswith extramedullary or central nervous system disease were excluded. Atbaseline, the median age was 24 (range, 19-38). Patients were heavilypretreated, with 5 median number of prior therapies (range, 1-9). Two patientshad high-risk disease and the median bone marrow tumor burden was a median of38.2% of blasts. None of the patients had undergone a prior allogeneic hematopoieticstem cell transplant.

Allpatients developed cytokine release syndrome (CRS), 4 of which were grade 3 and1 was grade 4. All cases were manageable and resolved with treatment andsupportive care. None of the patients developed neurotoxicity.

The completeremission (CR)/CR with incomplete hematologic recovery was 100%. By day 28, 4patients achieved a CR with negative for minimal residual disease (MRD) and 3of these patients remained MRD negative up to day 161. One patient achieved CRbut was MRD positive, and relapsed by day 29.

Peak CART-cell expansion in peripheral blood occurred between week 1 and 2.

As the first-in-human, universal CAR T-cell therapy for adult relapsed/refractory T-ALL, Dr Wang said, GC027 has demonstrated superior clinical efficacy and induced deep response in patients with acceptable safety profile. She added that trial enrollment is ongoing.

Read more of Cancer Therapy Advisors coverage of AACR 2020 meeting by visiting the conference page.

Reference

Wang X, Li S, Gao L, et al. Clinical safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I; April 27-28, 2020. Abstract CT052.

Here is the original post:
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL - Cancer Therapy Advisor

Bone Marrow Stem Cells Comments Off on First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL – Cancer Therapy Advisor | April 30th, 2020

Stem Cell Therapy market describes in-depth assessments and professional studies of the current and future status of the market worldwide, including valuable facts and figures. Stem Cell Therapy markets enhance this growth trend by providing information on new opportunities and market drivers, trends and future technologies. This report defines scope, coverage, production and CAGR (%) according to type, share, revenue status and outlook, capacity, consumption, market drivers, production status and outlook and opportunities, exports, imports, emerging market / national growth rates. This report provides a 360-degree overview of the industrys competitive environment. The Stem Cell Therapy market report evaluates key regions (countries) with a large market share during the forecast period.

Get sample copy of Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The research in its endeavor to present an unbiased presentation of the Stem Cell Therapy market, complete with multi-faceted documentation of various market forces that collectively lend enormous growth impetus to the Stem Cell Therapy market. This report further reinforces vital statistical data on technological marvels that under prevailing circumstances direct growth in the Stem Cell Therapy market. A holistic understanding on PESTEL and SWOT analysis are also tagged in the report to unearth peculiarities of the Stem Cell Therapy market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Stem Cell Therapy market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Stem Cell Therapy market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

This market ready research offering on Stem Cell Therapy market is a go-to synopsis that highlights on all the core developments simultaneously dominant across all regional hubs in the Stem Cell Therapy market and their subsequent implications on holistic growth trajectory of Stem Cell Therapy market globally. The report is aimed at answering all the relevant queries pertaining to the target market based on which successful business decisions could be rapidly applied, favoring uncompromised growth in the Stem Cell Therapy market.

The report also lends light on competition spectrum, highlighting core market participants who are identified as frontline players in Stem Cell Therapy market as highlighted by this research. In its bid to equip players with real time understanding of the various operational factors dominant across regions, the research elaborating on Stem Cell Therapy market also houses crucial data on various geographical hubs identified in Stem Cell Therapys market as presented.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

Bone Marrow Stem Cells Comments Off on Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 – Latest Herald | April 30th, 2020